The global exosome diagnostic and therapeutic market was valued at $224.3 million in 2020, and is projected to reach $2.92 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030. Exosomes are small extracellular vesicles present in various body fluids, such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger ribonucleic acid (mRNA), and micro ribonucleic acid (RNA). Presently, exosomes have great potential to be utilized for drug delivery and a biomarker for the diagnosis and testing of various diseases. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer. The global exosome diagnostic and therapeutic market is driven by increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations, rise in health awareness, technological advancements in exosomes isolation, surge in analytical procedures, and increase in innovative and advanced applications of exosomes. However, stringent government regulations for the approval of exosomes diagnostic and therapeutic products and lack of awareness about the applications of exosomes restrict the market growth.
Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.
The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).
Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.
The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Application
- Diagnostic
- Therapeutic
By Product
- Instrument
- Reagent
- Software
By End User
- Cancer Institute
- Hospital
- Diagnostic Center
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- NX Pharmagen, Inc.
- Sistemic Ltd
- Exosome Diagnostic, Inc.
- Capricor Therapeutics, Inc.
- NanoSomix, Inc
- System Biosciences, Inc
- Exiqon A/S
- Aethlon Medical, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to this report, the exosome diagnostic and therapeutic market was valued at $224.34 million in 2020, and is estimated to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes are used in two applications, which includes diagnostic and therapeutic. There are three types of products used in exosomes diagnostic and therapeutic technique, which include instrument, reagent, and software.Key factors driving the growth of the exosome diagnostic and therapeutic market due to increase in the number of neuro-degenerative and autoimmune diseases. Rise in application of exosome diagnostic and therapeutic technique for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and autoimmune disorders, such as diabetes and Rheumatoid arthritis are anticipated to drive the growth of the exosome diagnostic and therapeutic market. Exosomes are nanoparticles containing bioactive molecules reflecting individual physiological status, regulating metabolism, and repairing damaged tissues. They function as biomarkers of diabetes mellitus and diabetic complications. Thus, rise in prevalence of diabetes is anticipated to fuel the application of exosomes diagnostic and therapeutic technique. Therefore, this factor is anticipated to fuel the market growth. For instance, according to International Diabetes Federation (IDF), in 2021, approximately 537 million adults in the application of 20-79 were suffering from diabetes over the globe.
Moreover, The exosome diagnostic and therapeutic posses various applications in clinical research and it is used for liquid biopsy, copy number variation (CNV), rare sequence detection, gene expression, single-cell analysis, pathogen detection, microbiome analysis, and next-generation sequencing (NGS). The increase in number of contract research organizations (CRO) and research laboratories drives the growth of market. In addition, exosome diagnostic and therapeutic are also used in diagnostic centers for the diagnosis of various infectious diseases including COVID-19 detection. The rise in number of diagnostic centers boosts the growth of market. For instance, in October 2021, government of UK announced the launch of 40 community diagnostic centers across England.
Furthermore, exosomes helps in regulating complex intracellular and extracellular vesicles, hepatocellular carcinoma pathways that are advanced in their usefulness in the therapeutic control of several neurodegenerative conditions and cancer. Thus, rise in the prevalence of cancer is anticipated to fuel the demand for exosome diagnostic and therapeutic technique, which boosts the market growth. For instance, according to American Cancer Society, in 2022, it was estimated that 1,918,030 population is suffering from cancer. As per the same source, it was estimated that, number of deaths due to cancer were 609,360 in U. S. in 2022.
The market also offers growth opportunities to the key players in the market. Rise in the number of adoptions of key strategies, such as collaboration, acquisition, partnership, agreement, and others by market players who manufacture exosome diagnostic and therapeutic is anticipated to drive the market growth. For instance, in August 2020, Aethlon Medical announced collaboration with University of Pittsburgh for the study of depleting exosome to enhance response to immune therapy in head and neck squamous cell carcinoma. Moreover, increase in the number of product launch and product approvals for exosome diagnostic and therapeutic boosts the market growth. For instance, in April 2022, Bio-Techne Corporation announced product launch of exosome diagnostics, an ExoDx for prostate cancer test at home.
The exosome diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. On the basis of application, the market is classified into diagnostic and therapeutic. On the basis of product, it is classified into instrument, reagent, and software. On the basis of end user, the market is classified into cancer institute, hospital, diagnostic center, and other.
Region wise, the market is analyzed across North America (U. S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include Aethlon Medical, Inc., Bio-techne, NanoSomix Inc., Thermo Fisher Scientific Inc., Malvern Instruments Ltd., System Biosciences Inc., NX Pharmagen, Sistemic Inc., and Capricor Therapeutics, Exiqon A/S.
Key Market Insights (Updated)
By application, the diagnostic segment was the highest revenue contributor, whereas software and it is anticipated to grow at the highest CAGR of 29.5% during the forecast period
By product, the instrument segment was the highest revenue contributor, whereas software is anticipated to grow at the highest CAGR of 30.2% during the forecast period
By end user, the cancer institute segment was the highest revenue contributor, whereas diagnostic center is anticipated to grow at the highest CAGR of 30.3% during the forecast period
Based on region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 30.3% during the forecast period
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- NX Pharmagen, Inc.
- Sistemic Ltd
- Exosome Diagnostic, Inc.
- Capricor Therapeutics, Inc.
- NanoSomix, Inc
- System Biosciences, Inc
- Exiqon A/S
- Aethlon Medical, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
